share_log

The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery

The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery

杰克逊实验室和AbtherX宣布合作以加强治疗性抗体的发现
PR Newswire ·  05/10 17:21

BAR HARBOR, Maine and MOUNTAIN VIEW, Calif., May 10, 2024 /PRNewswire/ -- The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies. This collaboration will include co-development activities and leverages JAX's extensive experience in model research and AbTherx's Atlas Mouse platform to address critical challenges facing drug developers of all sizes.

缅因州巴尔港和加利福尼亚州山景城,2024年5月10日 /PRNewswire/ — 独立的非营利性生物医学研究组织杰克逊实验室(JAX)和生物技术创新者AbtherX宣布建立战略合作伙伴关系,开发和商业化尖端工具,以加快抗体发现,降低重要新疗法开发的风险。这种合作将包括共同开发活动,并利用JAX在模型研究方面的丰富经验和AbtherX的Atlas 鼠标平台可应对各种规模的药物开发商面临的关键挑战。

The Atlas Mouse technologies are engineered to leverage in vivo antibody selection and maturation processes for the creation of human antibodies and are specifically designed to overcome the limitations of historical antibody discovery technologies by offering enhanced speed, diversity, developability, and affinity. Such traits are essential for developing viable lead candidates more swiftly than traditional methods currently allow.

阿特拉斯 小鼠技术经过精心设计,旨在利用体内抗体选择和成熟过程来制造人体抗体,专为通过提高速度、多样性、可开发性和亲和力来克服历史抗体发现技术的局限性而设计。这些特征对于比目前传统方法所允许的更快地开发出可行的潜在候选人至关重要。

JAX will also become the exclusive distributor of select AtlasMouse models, including AbTherx's Full Human Diversity Mouse for monoclonal antibody development as well as the Binary Fixed Light Chain Mouse for bispecific and multispecific antibody development. JAX and AbTherx are additionally exploring opportunities to develop and distribute future models to expand on this existing suite of innovative tools.

JAX 还将成为精选 Atlas 的独家分销商小鼠模型,包括用于单克隆抗体开发的 AbtherX 全人类多样性小鼠以及用于双特异性和多特异性抗体开发的二元固定轻链小鼠。JAX 和 AbtherX 还在探索开发和分发未来模型的机会,以扩展这套现有的创新工具。

"By combining JAX's expertise in high-quality mouse models with the innovative capabilities of our Atlas Mouse platform, we are setting new industry standards," said Justin Mika, CEO of AbTherx. "This collaboration not only enhances our ability to create additional impactful technologies but also ensures that these advancements are within reach of researchers and developers globally, fostering a new era of medical innovation."

“通过将JAX在高质量鼠标模型方面的专业知识与我们的Atlas的创新能力相结合 鼠标平台,我们正在设定新的行业标准。” AbtherX首席执行官贾斯汀·米卡说。“这种合作不仅增强了我们创造更多有影响力的技术的能力,而且还确保了这些进步触手可及,从而推动了医学创新的新时代。”

"Providing access to high-quality research tools is paramount at The Jackson Laboratory, and we are thrilled to extend our capabilities with innovative models that are pivotal for the creation of new therapeutics," said Mitchell Kennedy, Executive Vice President of The Jackson Laboratory and President of JAX Mice, Clinical & Research Services. "Our partnership with AbTherx is a natural synergy, combining our decades of expertise in mouse model development with their deep knowledge in antibody discovery. Together, we are not only enhancing the tools available to researchers but also accelerating the pace at which impactful treatments can reach patients worldwide."

杰克逊实验室执行副总裁兼JAX小鼠、临床与研究服务总裁米切尔·肯尼迪表示:“在杰克逊实验室,提供获得高质量研究工具的途径至关重要,我们很高兴能够通过对开发新疗法至关重要的创新模型来扩展我们的能力。”“我们与AbtherX的合作是一种自然的协同作用,将我们在小鼠模型开发方面数十年的专业知识与他们在抗体发现方面的深厚知识相结合。我们共同努力,不仅增强了可供研究人员使用的工具,还加快了向全球患者提供有影响力的治疗的步伐。”

An early access program is set to launch in the second half of the year, during which time drug developers are invited to test and evaluate these groundbreaking platforms. For more details or to participate in the early access program, please contact JAX at [email protected].

一项抢先体验计划定于下半年启动,在此期间,药物开发商将被邀请测试和评估这些开创性的平台。欲了解更多详情或参与抢先体验计划,请通过 [email protected] 与 JAX 联系。

About The Jackson Laboratory

关于杰克逊实验室

The Jackson Laboratory is an independent, nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center and nearly 3,000 employees in locations across the United States, Japan, and China. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit .

杰克逊实验室是一家独立的非营利性生物医学研究机构,拥有国家癌症研究所指定的癌症中心,在美国、日本和中国各地有近 3,000 名员工。其使命是发现疾病的精确基因组解决方案,并赋予全球生物医学界权力,共同寻求改善人类健康。欲了解更多信息,请访问。

About AbTherx

关于 AbtherX

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx's passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit .

AbtherX 正在通过革命性技术推动医学发展,这些技术可以加速和促进治疗性抗体的发现。通过与吉利德科学的独家合作,abtherX 发布了 Atlas 小鼠,一套专为无与伦比的性能和FTO而设计的新型转基因技术。20多年来,AbtherX充满激情、富有创新精神和协作精神的团队突破了抗体发现技术的界限,成功开展了1,000多项抗体发现活动和13种上市疗法。AbtherX 行业领先的团队创造了变革性解决方案,以克服在交付创新药物方面最严峻的挑战。AbtherX 致力于让所有人都能使用其技术,提供灵活的合作模式,以满足各种规模的药物开发商的需求。欲了解更多信息,请访问。

SOURCE The Jackson Laboratory

来源:杰克逊实验室

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发